Is There Any Role of Adjuvant Chemotherapy for T3N0M0 or T1N2M0 Gastric Cancer Patients in Stage II in the 7th TNM but Stage I in the 6th TNM System?

详细信息    查看全文

• 作者：Kyung-Goo Lee MD ; Hyuk-Joon Lee MD ; PhD ; Seung-Young Oh MD…
• 刊名：Annals of Surgical Oncology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：23
• 期：4
• 页码：1234-1243
• 全文大小：830 KB
• 参考文献：1.Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRef PubMed
  2.Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat. 2014;46(2):109–23.CrossRef PubMed PubMedCentral
  3.Ahn HS, Lee HJ, Yoo MW, Jeong SH, Park DJ, Yang HK. Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period. Br J Surg. 2011;98(2):255–60.CrossRef PubMed
  4.Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.CrossRef PubMed
  5.Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRef PubMed
  6.Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.CrossRef PubMed
  7.Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.CrossRef PubMed
  8.Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93.CrossRef PubMed
  9.Bang YJ, Kim YW, Noh SH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21.CrossRef PubMed
  10.Noh SH, Park SR, Bang YJ, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389–96.CrossRef PubMed
  11.Ajani JA, Bentrem DJ, Besh S, et al. National Comprehensive Cancer Network. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013;11(5):531–46.PubMed
  12.Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. European Society for Medical Oncology (ESMO); European Society of Surgical Oncology (ESSO); European Society of Radiotherapy and Oncology (ESTRO). Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi57–63.
  13.Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14(2):113–23.CrossRef
  14.Lee JH, Kim JG, Jung HK, et al. Synopsis on clinical practice guideline of gastric cancer in Korea: an evidence-based approach. Korean J Gastroenterol. 2014;63(2):66–81.CrossRef PubMed
  15.Sobin LH, Wittekind CH, eds. TNM classification of malignant tumors. 6th ed. New York: Wiley; 2002.
  16.Greene FL, Page DL, Fleming ID, et al. (eds). AJCC cancer staging manual: TNM classification of malignant tumors. 6th ed. New York: Springer; 2002.
  17.Edge SB, Byrd DR, Compton CC, et al. (eds). AJCC cancer staging handbook. 7th ed. New York: Springer; 2010.
  18.Ahn HS, Lee HJ, Yang HK, et al. Evaluation of the seventh American Joint Committee on Cancer/International Union Against Cancer Classification of gastric adenocarcinoma in comparison with the sixth classification. Cancer. 2010;116(24):5592–8.CrossRef PubMed
  19.Songun I, Putter H, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.CrossRef PubMed
  20.Wu CW, Hsiung CA, Li AF, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7(4):309–15.CrossRef PubMed
  21.Degiuli M, Sasako M, Ponti A; Italian Gastric Cancer Study Group. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg. 2010;97(5):643–9.CrossRef PubMed
  22.Kim NK, Park YS, Heo DS, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993;71(12):3813–8.CrossRef PubMed
  23.Chang HM, Jung KH, Kim NK, et al. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer. Ann Oncol. 2002;13(11):1779–85.CrossRef PubMed
  24.GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729–37.
  25.Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Lancet. 1999;354(9175):273–7.CrossRef PubMed
  26.Nashimoto A, Nakajima T, Furukawa H, et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol. 2003;21(12):2282–7.CrossRef PubMed
  27.Warneke VS, Behrens HM, Hartmann JT, Held H, Becker T, Schwarz NT, et al. Cohort study based on the seventh edition of the TNM classification for gastric cancer: proposal of a new staging system. J Clin Oncol. 2011;29(17):2364–71.CrossRef PubMed
  28.Baiocchi GL, Tiberio GA, Minicozzi AM, et al. A multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. Ann Surg. 2010;252(1):70–3.CrossRef PubMed
  29.Saito H, Kuroda H, Matsunaga T, et al. Prognostic indicators in node-negative advanced gastric cancer patients. J Surg Oncol. 2010;101(7):622–5.CrossRef PubMed
  30.Lee IS, Yook JH, Kim TH, et al. Prognostic factors and recurrence pattern in node-negative advanced gastric cancer. Eur J Surg Oncol. 2013;39(2):136–40.CrossRef PubMed
  31.Huang CM, Wang HM, Zheng CH, et al. Tumor size as a prognostic factor in patients with node-negative gastric cancer invading the muscularis propria and subserosa (pT2-3N0M0 stage). Hepatogastroenterology. 2013;60(124):699–703.PubMed
  32.Kooby DA, Suriawinata A, Klimstra DS, Brennan MF, Karpeh MS. Biologic predictors of survival in node-negative gastric cancer. Ann Surg. 2003;237(6):828–35.PubMed PubMedCentral
  33.Soga K, Ichikawa D, Yasukawa S, Kubota T, Kikuchi S, Otsuji E. Prognostic impact of the width of subserosal invasion in gastric cancer invading the subserosal layer. Surgery. 2010;147(2):197–203.CrossRef PubMed
  34.Gunji Y, Suzuki T, Hori S, Hayashi H, Matsubara H, Ochiai T. Prognostic significance of the number of metastatic lymph nodes in early gastric cancer. Dig Surg. 2003;20(2):148–53.CrossRef PubMed
  35.Huang B, Zheng X, Wang Z, Wang M, Dong Y, Xu H. Prognostic significance of the number of metastatic lymph nodes: is UICC/TNM node classification perfectly suitable for early gastric cancer? Ann Surg Oncol. 2009;16(1):61–7.CrossRef PubMed
  36.Shimada S, Yagi Y, Honmyo U, Shiomori K, Yoshida N, Ogawa M. Involvement of three or more lymph nodes predicts poor prognosis in submucosal gastric carcinoma. Gastric Cancer. 2001;4(2):54–9.CrossRef PubMed
  37.Lee HJ, Kim YH, Kim WH, Lee KU, Choe KJ, Yang HK. Clinicopathological analysis for recurrence of early gastric cancer. Jpn J Clin Oncol. 2003;33(5):209–14.CrossRef PubMed
  38.Saka M, Katai H, Fukagawa T, Nijjar R, Sano T. Recurrence in early gastric cancer with lymph node metastasis. Gastric Cancer. 2008;11(4):214–8.CrossRef PubMed
  39.Suh YS, Han DS, Yang HK, et al. Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification. Ann Surg. 2012;255(5):908–15.CrossRef PubMed
  
• 作者单位：Kyung-Goo Lee MD (1) (5)
  Hyuk-Joon Lee MD, PhD (1) (4)
  Seung-Young Oh MD (1)
  Jun-Young Yang MD (1)
  Hye-Seong Ahn MD (1)
  Yun-Suhk Suh MD (1)
  Seong-Ho Kong MD, PhD (1)
  Tae-Yong Kim MD, PhD (2)
  Do-Youn Oh MD, PhD (2) (4)
  Seock-Ah Im MD, PhD (2) (4)
  Kuhn Uk Lee MD, PhD (1) (5)
  Woo Ho Kim MD, PhD (3)
  Yung-Jue Bang MD, PhD (2) (4)
  Han-Kwang Yang MD, PhD (1) (4)
  
  1. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea
  5. Department of Surgery, Myongji Hospital, Goyang, Korea
  4. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
  2. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
  3. Department of Pathology, Seoul National University College of Medicine, Seoul, Korea
  
• 刊物主题：Surgical Oncology; Oncology; Surgery;
• 出版者：Springer US
• ISSN：1534-4681

文摘

Background Controversy surrounds adjuvant chemotherapy (CTx) for T3N0M0 and T1N2M0 in the American Joint Committee on Cancer (AJCC) 7th edition stage IIA gastric cancer patients. The purpose of this study was to evaluate the benefit of adjuvant CTx for stage IIA cancer, including T3N0M0 and T1N2M0.